No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
455 |
4. Check minimum number of eventsNone |
455 |
5. Include endpointsNone |
455 |
6. Filter based on genotype QC (FinnGen only) |
455 |
Control definitions (FinnGen only)
- Control exclude
- H7_SCLERACORNEA
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- H15
- Name in latin
- Scleritis
Similar endpoints
↥List of similar endpoints to
Scleritis
based on the number of shared cases.
Similar with more cases:
- Scleritis and episcleritis
- Disorders of sclera, cornea, iris and ciliary body
- Diseases of the eye and adnexa
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2446 | 1435 | 995 |
| Only index persons | 2329 | 1379 | 950 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.04 | 0.03 |
| Only index persons | 0.04 | 0.05 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 51.11 | 53.37 | 48.04 |
| Only index persons | 50.92 | 53.12 | 47.73 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 455 | 315 | 140 |
| Unadjusted period prevalence (%) | 0.09 | 0.11 | 0.06 |
| Median age at first event (years) | 52.91 | 51.73 | 55.59 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 400
- Matched controls
- 3999
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H15.0
ICD-10 Finland
Scleritis
4503599627370496.0
323.0
392
*
H15.1
ICD-10 Finland
Episcleritis
776.6
162.2
149
*
H20.0
ICD-10 Finland
Acute and subacute iridocyclitis
1508.1
119.1
110
*
H57.1
ICD-10 Finland
Ocular pain
25.6
59.3
84
41
S01CA01
ATC
dexamethasone and antiinfectives; ophthalmic (ophth., corticosteroids and antiinfectives in comb.)
5.3
51.5
225
784
H02AB06
ATC
prednisolone; systemic
4.3
40.6
271
1319
H04.10
ICD-10 Finland
Dry eye syndrome
6.8
35.8
98
181
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
3.8
35.2
233
1068
H16.0
ICD-10 Finland
Corneal ulcer
22.7
34.5
50
25
Z01.0
ICD-10 Finland
Examination of eyes and vision
4.9
31.4
117
309
S01BA01
ATC
dexamethasone; ophthalmic (corticosteroids, plain)
12.6
30.7
56
51
H16.9
ICD-10 Finland
Keratitis, unspecified
+∞
29.5
28
*
H20.1
ICD-10 Finland
Chronic iridocyclitis
+∞
28.5
27
*
H20.9
ICD-10 Finland
Iridocyclitis, unspecified
150.1
27.0
28
*
S01BC03
ATC
diclofenac; ophthalmic
14.3
26.4
45
35
H10.3
ICD-10 Finland
Acute conjunctivitis, unspecified
7.9
26.1
62
91
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
5.1
25.9
89
211
A02BC02
ATC
pantoprazole; systemic
3.3
24.3
308
2023
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
4.5
23.3
91
245
L04AX01
ATC
azathioprine; systemic
6.8
19.4
50
82
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.7
18.8
196
1060
XCW99
NOMESCO Finland
Other investigative procedure of eye
4.3
18.8
76
209
S01BA04
ATC
prednisolone; ophthalmic (corticosteroids, plain)
12.3
17.8
32
28
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.7
17.8
156
758
H02AB07
ATC
prednisone; oral
3.5
17.5
93
319
A07EC01
ATC
sulfasalazine; oral, rectal
4.1
15.4
64
179
XCD10
NOMESCO Finland
Electrophysiological examination of eye
8.9
14.3
30
36
S01AD03
ATC
aciclovir; ophthalmic
9.4
14.2
29
33
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
22.1
13.5
19
9
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
4.8
13.3
45
103
H10.9
ICD-10 Finland
Conjunctivitis, unspecified
5.0
13.3
43
94
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
4.0
13.2
54
149
XCK10
NOMESCO Finland
Photography of fundus of eye
4.0
13.0
54
151
S01ED01
ATC
timolol; ophthalmic
10.1
11.9
23
24
H20.8
ICD-10 Finland
Other iridocyclitis
+∞
11.5
11
*
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
3.6
11.2
52
160
R51.80
ICD-10 Finland
Headache
2.7
11.1
83
353
S01BC05
ATC
ketorolac; ophthalmic
6.3
11.1
29
49
K50.8
ICD-10 Finland
Other Crohn disease
11.0
10.9
20
19
S01ED51
ATC
timolol, combinations; ophthalmic
4.5
10.8
38
91
H19.1*B00.5
ICD-10 Finland
Herpesviral keratoconjunctivitis
+∞
10.5
10
*
F01
ICPC
Eye pain
7.4
10.4
24
34
S01EA05
ATC
brimonidine; ophthalmic (sympathomimetics in glaucoma therapy)
15.1
10.1
16
11
H20
ICD-10 Finland
Iridocyclitis
+∞
9.4
9
*
TCA20
NOMESCO Finland
Peribulbar therapeutic injection into orbit
+∞
9.4
9
*
N02BE01
ATC
paracetamol; systemic, rectal
2.4
9.4
347
2926
S01CA02
ATC
prednisolone and antiinfectives; ophthalmic (ophth., corticosteroids and antiinfectives in comb.)
14.1
9.2
15
11
M25.5
ICD-10 Finland
Pain in joint
2.1
9.2
137
807
F02
ICPC
Red eye
4.6
9.1
31
72
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
4.9
9.1
29
63
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
3.2
8.8
46
155
CF2S4
NOMESCO Finland
Photography of conjunctiva
91.9
8.4
9
*
36904
ICD-8 Finland
Other inflammatory diseases of eye, Scleritis
+∞
8.4
8
*
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
7.3
8.3
19
27
H10
ICD-10 Finland
Conjunctivitis
3.5
8.3
38
116
Z96.1
ICD-10 Finland
Presence of intraocular lens
3.0
8.3
48
174
J01.0
ICD-10 Finland
Acute maxillary sinusitis
2.1
8.2
104
569
J01AA02
ATC
doxycycline; systemic
2.0
8.2
311
2545
P01BA02
ATC
hydroxychloroquine; oral
2.9
8.2
51
194
H11.3
ICD-10 Finland
Conjunctival haemorrhage
4.8
8.2
26
57
J01MA12
ATC
levofloxacin; systemic
2.3
8.1
78
378
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
3.5
8.0
37
114
J01FF01
ATC
clindamycin; systemic
2.0
7.7
114
665
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
2.8
7.6
51
201
M01AE02
ATC
naproxen; oral, rectal
1.8
7.6
236
1776
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.3
7.5
74
363
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
4.2
7.4
27
68
H53.1
ICD-10 Finland
Subjective visual disturbances
3.3
7.3
36
117
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
4.8
7.3
23
50
H18.8
ICD-10 Finland
Other specified disorders of cornea
+∞
7.3
7
*
UJF32
NOMESCO Finland
Coloscopy
2.0
7.3
101
571
H40.5
ICD-10 Finland
Glaucoma secondary to other eye disorders
20.4
7.2
10
5
H57.9
ICD-10 Finland
Disorder of eye and adnexa, unspecified
12.3
7.1
12
10
J01FA09
ATC
clarithromycin; systemic
1.9
7.1
138
884
A02BC03
ATC
lansoprazole; oral
1.9
7.1
119
724
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
2.9
7.1
41
149
M46.9
ICD-10 Finland
Inflammatory spondylopathy, unspecified
10.3
7.1
13
13
XCH00
NOMESCO Finland
Eye pressure measurement
4.4
7.0
24
57
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.9
7.0
112
668
R51.81
ICD-10 Finland
Facial pain NOS
6.5
7.0
17
27
S01FA04
ATC
cyclopentolate; ophthalmic
11.2
6.8
12
11
R07.4
ICD-10 Finland
Chest pain, unspecified
2.0
6.8
101
585
NH3BA
NOMESCO Finland
Foot and toes extensive X-ray examination
4.1
6.8
25
64
K50.9
ICD-10 Finland
Crohn disease, unspecified
7.4
6.8
15
21
CJE20
NOMESCO Finland
Phakoemulsification with implantation of artificial lens in posterior chamber
2.0
6.7
88
486
J01MA02
ATC
ciprofloxacin; systemic
1.8
6.6
145
962
E0000UV
ATC
NA
1.8
6.5
165
1142
J01FA10
ATC
azithromycin; systemic
1.7
6.5
244
1900
CG2X4
NOMESCO Finland
Optical coherence tomography (OCT) of cornea
70.9
6.4
7
*
M79.6
ICD-10 Finland
Pain in limb
1.8
6.4
142
940
R51
ICD-10 Finland
Headache
3.1
6.4
33
112
L30.9
ICD-10 Finland
Dermatitis, unspecified
2.1
6.4
75
396
T15.0
ICD-10 Finland
Foreign body in cornea
4.7
6.4
20
44
G44.2
ICD-10 Finland
Tension-type headache
2.3
6.3
62
300
R06.0
ICD-10 Finland
Dyspnoea
2.0
6.3
92
527
K50.0
ICD-10 Finland
Crohn disease of small intestine
7.2
6.3
14
20
H16.8
ICD-10 Finland
Other keratitis
+∞
6.3
6
*
H16.2
ICD-10 Finland
Keratoconjunctivitis
+∞
6.3
6
*
TCF00
NOMESCO Finland
Subconjunctival therapeutic injection
+∞
6.3
6
*
S01EC01
ATC
acetazolamide; systemic
8.8
6.1
12
14
H10.0
ICD-10 Finland
Mucopurulent conjunctivitis
3.2
6.1
30
99
TAB00
NOMESCO Finland
Lumbar puncture
3.7
6.0
24
67
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
95
113
10.36
76.68
1.8
1.6
—
137.5
—
0
8
54
62
9.75
44.03
1.5
1.2
156.0
—
titre
—
5
0
187
704
3.81
41.16
1.6
1.3
64.3
30.8
iu/ml
0.60
62
238
64
109
6.67
37.11
1.7
1.6
0.1
0.1
iu/ml
0.20
12
14
28
16
18.58
34.46
1.3
3.9
496.8
673.9
u/ml
0.36
28
16
345
2154
3.49
30.07
13.0
8.7
4.2
4.0
e9/l
1.00
323
1889
304
1795
3.09
28.53
10.6
5.5
28.5
28.5
%
0.04
298
1675
299
1776
2.99
27.25
10.3
5.3
56.9
57.0
%
0.09
293
1664
58
132
4.89
24.38
1.8
1.4
1.3
1.2
g/l
0.27
53
126
384
2777
3.45
21.94
7.7
3.7
13.2
10.9
mm/h
2.27
374
2575
145
693
2.60
18.63
1.4
1.3
2.8
9.8
u/ml
2.51
42
291
20
5
41.76
16.46
1.4
1.0
—
—
—
0
0
275
1823
2.29
16.16
7.9
4.5
0.0
0.0
estimate
0.50
47
362
273
1813
2.26
15.85
5.9
3.3
0.0
0.0
estimate
0.00
46
359
49
136
3.92
15.82
1.3
1.7
—
—
—
0
0
203
1199
2.25
15.68
5.3
3.0
—
—
—
0
0
370
2825
2.66
15.22
11.1
6.9
74.2
76.5
u/l
0.57
361
2653
274
1842
2.23
15.17
5.9
3.3
0.0
0.0
estimate
0.80
43
351
237
1526
2.15
14.37
7.3
5.4
1.2
1.2
mmol/l
0.51
221
1382
22
34
6.75
13.77
1.4
1.1
—
—
—
0
0
22
34
6.75
13.77
1.4
1.1
—
—
—
0
0
22
35
6.55
13.40
1.4
1.1
—
—
—
0
0
22
35
6.55
13.40
1.4
1.1
—
—
—
0
0
22
35
6.55
13.40
1.4
1.1
—
—
—
0
0
26
50
5.45
13.11
1.0
1.1
—
—
—
0
0
110
539
2.37
12.84
4.0
2.6
0.6
1.0
e6/l
2.15
72
297
23
41
5.86
12.54
1.3
1.2
—
—
—
0
0
228
1505
2.03
12.31
3.3
2.2
76.5
75.8
nmol/l
0.12
214
1361
21
36
6.07
11.90
1.2
1.2
—
—
—
0
0
38
108
3.75
11.84
1.2
1.2
4.0
2.7
u/ml
—
6
16
245
1676
2.00
11.79
8.5
6.2
1.2
1.2
mmol/l
0.09
214
1413
38
110
3.68
11.53
1.2
1.2
1.9
6.2
u/ml
—
7
22
29
71
4.29
11.04
2.3
1.5
8062.8
7590.9
e6/l
0.04
23
53
15
20
7.72
10.62
1.2
1.2
—
—
—
0
0
214
1446
1.91
10.20
5.9
4.3
36.0
36.1
g/l
0.14
201
1355
433
3803
3.87
9.99
21.7
12.0
16.8
21.7
mg/l
3.80
379
2936
195
1288
1.90
9.88
3.9
3.3
35.8
32.6
ng/l
0.09
132
813
28
73
4.02
9.82
2.1
1.3
—
—
—
0
0
99
515
2.18
9.80
1.9
1.8
—
—
—
0
0
46
170
2.90
9.41
1.5
1.6
—
—
—
0
0
147
929
1.86
8.25
4.7
2.9
0.1
0.4
e6/l
2.38
108
682
270
2047
1.78
8.19
5.8
4.2
6.4
6.6
mmol/l
0.39
256
1903
13
20
6.66
8.10
1.4
1.2
—
—
—
0
0
60
273
2.38
8.09
6.0
3.2
1.2
2.1
mmol/l
1.04
54
220
52
223
2.50
7.97
1.5
1.5
—
—
—
0
0
13
21
6.34
7.75
2.6
2.1
16.8
12.8
%
—
5
13
159
1046
1.80
7.74
2.2
2.0
211.2
177.0
u/l
0.14
152
991
133
829
1.85
7.72
2.7
2.0
2.7
3.1
mg/l
1.25
123
715
71
360
2.15
7.39
2.0
1.8
—
—
—
0
0
70
355
2.15
7.28
1.9
1.8
—
—
—
0
0
31
106
3.07
7.27
1.4
1.2
—
—
—
0
0
10
5
20.40
7.16
1.0
1.0
—
—
—
0
0
200
1430
1.71
7.14
6.0
3.3
—
—
—
0
0
88
494
1.97
6.95
2.3
1.9
29.6
29.4
s
0.14
88
482
100
588
1.90
6.88
2.1
2.7
2.5
2.4
mmol/l
0.39
89
517
13
24
5.55
6.80
2.0
1.6
875.0
637.6
e6/l
—
8
12
140
921
1.75
6.65
3.5
2.4
2784.6
6648.0
umol/l
0.71
130
816
144
959
1.73
6.53
6.8
3.6
0.0
0.0
estimate
0.50
48
355
24
75
3.32
6.52
1.4
1.2
—
—
—
0
0
168
1171
1.69
6.43
2.7
3.4
2.4
2.4
mmol/l
0.39
149
1031
23
71
3.36
6.36
1.5
1.2
305.3
232.8
u/ml
0.59
16
43
127
822
1.76
6.35
1.9
1.7
0.9
0.9
mg/l
0.03
96
630
186
1336
1.66
6.33
2.2
1.9
99.5
96.0
pmol/l
0.33
93
703
12
22
5.58
6.32
4.7
3.5
—
—
—
0
0
52
249
2.23
6.22
2.4
2.4
4.0
6.3
ug/l
1.51
45
226
28
100
2.92
6.11
1.1
1.1
—
—
—
0
0
22
68
3.35
6.08
3.4
3.8
56.6
60.2
%
0.47
22
68
130
857
1.72
6.05
2.5
2.1
—
—
—
0
0
92
548
1.85
6.03
1.7
1.7
1281.9
1192.1
nmol/l
0.43
75
408
31
118
2.75
6.03
2.1
2.0
7.2
7.3
g/l
0.13
26
94
31
118
2.75
6.03
2.1
2.0
3.9
3.8
g/l
0.12
26
89
31
118
2.75
6.03
2.1
2.0
—
—
—
0
0
242
1877
1.62
5.94
6.0
6.0
9.8
10.6
umol/l
0.85
233
1777
86
505
1.87
5.89
4.1
2.7
3.9
3.2
e6/l
0.14
45
264
11
20
5.61
5.83
2.6
2.1
—
—
—
0
0
13
28
4.75
5.77
1.0
1.1
—
—
—
0
0
77
439
1.91
5.77
3.0
2.2
22.7
23.1
%
0.08
70
382
120
783
1.72
5.76
1.5
1.4
19.6
21.3
nmol/l
0.58
106
672
423
3848
2.41
5.71
19.8
13.3
139.6
139.7
mmol/l
0.36
418
3747
21
66
3.29
5.66
3.2
3.3
4.0
4.7
e9/l
0.61
21
66
21
66
3.29
5.66
1.2
1.4
—
—
—
0
0
10
17
5.99
5.65
1.0
1.1
1320.7
1617.1
miu/ml
—
10
17
397
3533
1.97
5.58
5.6
4.7
1.9
2.2
mu/l
0.34
369
3270
41
186
2.32
5.57
6.7
8.1
0.8
0.7
%
1.10
41
186
13
29
4.59
5.54
2.6
1.1
—
—
—
0
0
27
100
2.81
5.53
1.3
1.3
—
—
—
0
0
66
364
1.95
5.44
25.9
17.8
1.3
1.3
inr
0.05
13
52
423
3861
2.36
5.43
20.2
13.4
3.9
3.9
mmol/l
0.62
417
3751
56
292
2.05
5.40
2.2
2.2
67.6
68.5
ml/min/173m2
0.05
23
114
20
63
3.27
5.38
1.8
1.2
109.9
107.5
u/ml
—
8
15
9
8
11.44
5.31
1.0
1.0
—
—
—
0
0
9
8
11.44
5.31
1.0
1.0
107.0
102.8
%
—
9
8
118
785
1.68
5.22
6.9
3.4
1.0
1.0
kg/l
0.72
17
103
438
4075
3.00
5.16
17.1
9.4
26.7
26.4
u/l
0.08
429
3954
157
1127
1.60
5.12
3.2
2.3
54.7
56.7
u/l
0.38
143
1049
14
36
3.98
5.02
1.1
1.1
—
—
—
0
0
219
1709
1.54
4.90
3.5
2.7
114.1
95.3
ug/l
0.97
210
1592
11
24
4.67
4.80
1.0
1.0
—
—
—
0
0
26
105
2.57
4.55
1.2
1.2
363.7
403.0
mg/l
0.51
26
100
116
797
1.61
4.46
1.9
1.5
—
—
—
0
0
124
869
1.59
4.38
3.3
3.0
834.1
1017.1
ng/l
0.40
112
724
23
95
2.50
3.87
1.1
1.2
4.0
3.8
mmol/l
0.30
23
89
30
140
2.22
3.86
6.3
3.3
58.4
48.6
%
1.23
30
140
337
2969
1.52
3.72
4.8
4.0
14.8
14.6
pmol/l
1.03
312
2725
15
50
3.07
3.72
1.1
1.3
0.7
0.5
nmol/l
1.04
15
45
8
12
6.76
3.68
2.0
1.8
—
—
—
0
0
16
56
2.92
3.66
2.8
2.7
—
982.0
—
0
6
446
4291
2.99
3.56
31.5
17.9
135.3
135.8
g/l
0.32
446
4236
13
41
3.23
3.52
1.5
1.7
—
—
—
0
0
57
345
1.75
3.51
2.0
1.9
329.5
382.2
nmol/l
1.20
51
323
12
36
3.40
3.50
1.5
1.8
—
—
—
0
0
67
429
1.66
3.37
9.4
6.3
—
—
—
0
0
27
128
2.18
3.37
3.6
2.2
1.9
1.5
g/l
0.58
22
111
11
32
3.50
3.35
1.5
1.9
—
—
—
0
0
17
65
2.68
3.34
1.6
1.3
—
—
—
0
0
17
65
2.68
3.34
1.6
1.3
—
—
—
0
0
15
54
2.84
3.28
1.6
1.8
—
—
—
0
0
15
56
2.74
3.08
1.1
1.1
—
—
—
0
0
10
30
3.39
2.92
1.5
1.1
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
17
70
2.48
2.91
2.2
2.5
0.3
0.3
u/ml
—
10
41
24
116
2.13
2.88
2.7
3.3
24.7
25.0
mmol/l
0.18
24
111
45
270
1.74
2.88
1.6
2.0
—
—
—
0
0
19
83
2.35
2.88
1.2
1.1
—
—
—
0
0
13
47
2.82
2.84
1.8
2.1
12.7
22.8
mg/l
—
7
15
10
31
3.28
2.79
1.4
1.7
—
—
—
0
0
10
31
3.28
2.79
1.4
1.7
—
—
—
0
0
10
31
3.28
2.79
1.4
1.7
—
—
—
0
0
25
125
2.06
2.76
1.4
1.5
—
—
—
0
0
21
98
2.20
2.75
3.5
2.9
—
—
—
0
0
13
48
2.76
2.74
1.0
1.1
—
—
—
0
0
33
183
1.87
2.73
2.7
3.0
0.9
2.0
mmol/l
0.96
26
135
391
3628
1.55
2.72
17.4
10.9
83.8
85.0
ml/min/173m2
0.51
344
2943
395
3677
1.56
2.67
4.8
4.1
5.8
5.8
mmol/l
0.02
379
3398
13
50
2.65
2.55
1.0
1.1
—
—
—
0
0
17
75
2.32
2.54
1.6
1.6
—
—
—
0
0
302
2688
1.37
2.53
3.3
3.3
—
—
—
0
0
23
116
2.04
2.50
1.4
1.7
—
—
—
0
0
118
908
1.40
2.50
1.4
1.2
1.3
1.6
u/ml
0.30
29
270
9
26
3.51
2.49
1.0
1.8
—
—
—
0
0
131
1028
1.39
2.47
4.9
4.0
24.6
9.8
mg/mmol
1.27
92
628
85
618
1.46
2.45
4.0
3.4
581.1
282.0
ng/l
0.25
65
433
374
3466
1.44
2.35
6.1
5.1
39.5
39.2
mmol/mol
0.21
356
3254
52
344
1.58
2.32
6.5
7.1
0.1
1.3
mmol/l
1.81
46
276
6
13
4.66
2.28
2.7
6.2
—
—
—
0
0
5
9
5.60
2.22
1.4
2.4
117.0
140.3
%
—
5
9
16
74
2.20
2.17
1.6
1.8
—
—
—
0
0
23
124
1.90
2.11
1.6
1.8
—
—
—
0
0
35
215
1.68
2.10
1.3
1.9
—
—
—
0
0
8
25
3.24
2.10
1.0
1.1
—
—
—
0
0
50
338
1.54
2.05
4.0
2.2
24.9
33.8
u/l
1.67
43
290
6
15
4.04
2.04
1.0
1.3
—
—
—
0
0
12
50
2.44
2.04
1.5
1.2
—
—
—
0
0
11
44
2.54
2.02
1.3
1.4
—
—
—
0
0
11
44
2.54
2.02
1.3
1.4
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
8
26
3.11
2.02
1.0
1.2
—
—
—
0
0
8
26
3.11
2.02
1.3
1.1
—
—
—
0
0
13
57
2.32
1.99
1.5
1.7
—
—
—
0
0
16
77
2.12
1.99
1.6
1.8
—
—
—
0
0
11
45
2.48
1.94
1.3
1.4
—
—
—
0
0
11
45
2.48
1.94
1.6
1.6
—
—
—
0
0
28
167
1.72
1.89
3.8
2.7
0.5
0.1
e6/l
0.40
28
160
19
100
1.94
1.88
2.8
2.1
225.2
240.6
ug/l
0.03
14
93
11
46
2.43
1.86
1.3
1.3
—
—
—
0
0
11
46
2.43
1.86
1.3
1.4
—
—
—
0
0
11
46
2.43
1.86
1.3
1.4
—
—
—
0
0
13
59
2.24
1.86
1.1
1.1
—
—
—
0
0
6
17
3.56
1.84
1.2
1.6
—
—
—
0
0
6
18
3.36
1.75
1.0
1.0
—
—
—
0
0
153
1288
1.28
1.71
2.7
3.0
32.9
31.6
u/l
0.14
146
1229
10
42
2.41
1.69
1.6
1.6
—
—
—
0
0
37
246
1.55
1.66
2.8
3.5
4.3
4.6
pmol/l
1.49
28
217
198
1727
1.26
1.64
4.2
3.8
—
—
—
0
0
5
14
3.60
1.62
1.2
1.2
13.2
15.3
u/l
—
5
14
10
43
2.36
1.61
1.0
1.1
—
—
—
0
0
56
409
1.42
1.60
2.6
2.3
5.3
7.4
umol/l
1.33
49
350
5
15
3.36
1.52
1.4
2.1
75.1
65.0
ug/l
—
5
15
7
28
2.52
1.45
1.1
1.3
1.7
1.9
mmol/l
—
7
28
13
66
2.00
1.44
1.7
2.0
125.3
131.8
g/l
—
6
50
7
29
2.44
1.39
2.7
3.8
—
—
—
0
0
10
47
2.15
1.34
1.6
1.6
—
—
—
0
0
86
694
1.29
1.32
1.6
1.6
109210964.5
46064091.2
pmol/l
0.24
76
597
14
76
1.87
1.31
1.1
1.1
0.6
2.0
u/ml
—
6
27
30
202
1.52
1.31
2.0
1.4
—
—
—
0
0
8
34
2.38
1.29
1.0
1.0
—
—
—
0
0
5
18
2.80
1.29
1.2
1.5
36.0
32.6
umol/l
—
5
18
12
62
1.96
1.29
2.2
1.5
—
—
—
0
0
290
2692
1.21
1.19
3.3
2.9
44.2
44.5
u/l
0.02
276
2546
5
20
2.52
1.15
1.2
1.1
—
—
—
0
0
402
3873
1.33
1.14
5.3
4.5
2.9
2.9
mmol/l
0.00
381
3610
36
262
1.41
1.09
4.5
4.1
1.2
1.2
mmol/l
0.92
31
234
5
21
2.40
1.09
2.2
3.0
—
—
—
0
0
19
122
1.58
1.04
1.2
1.2
—
—
—
0
0
19
123
1.57
1.01
1.2
1.2
—
—
—
0
0
18
116
1.57
0.98
1.6
1.7
—
—
—
0
0
6
28
2.16
0.92
1.5
1.5
—
—
—
0
0
11
63
1.76
0.91
1.2
1.1
—
—
—
0
0
24
169
1.44
0.89
1.5
1.4
—
—
—
0
0
10
56
1.80
0.88
1.4
1.2
—
—
—
0
0
18
120
1.52
0.86
1.2
1.1
—
5.7
—
0
21
113
987
1.19
0.86
1.7
1.6
1.4
1.4
mmol/l
0.10
97
852
44
346
1.30
0.85
2.8
3.2
—
—
—
0
0
56
459
1.25
0.80
1.6
2.0
—
—
—
0
0
0
25
0.00
0.79
0.0
1.6
—
—
—
0
0
6
34
1.77
0.76
2.0
1.7
—
—
—
0
0
62
523
1.21
0.69
1.7
2.1
—
—
—
0
0
7
43
1.64
0.67
1.1
1.3
—
—
—
0
0
12
78
1.55
0.66
1.3
1.4
—
—
—
0
0
73
630
1.19
0.65
3.4
3.8
26.4
21.9
%
1.73
37
264
5
29
1.73
0.64
1.2
1.2
—
0.1
u/ml
—
0
11
13
87
1.51
0.64
2.5
1.6
—
—
—
0
0
379
3682
1.18
0.62
4.4
3.7
1.4
1.3
mmol/l
1.98
356
3423
392
3825
1.18
0.57
4.9
4.1
4.8
4.8
mmol/l
0.15
373
3592
6
37
1.63
0.55
1.2
1.1
—
—
—
0
0
50
424
1.20
0.55
4.4
4.2
30.1
31.6
%
0.45
40
276
390
3813
1.16
0.49
4.8
4.1
1.5
1.5
mmol/l
0.39
368
3558
23
182
1.28
0.47
1.5
1.8
5.3
3.0
mg/l
0.93
23
137
5
31
1.62
0.43
1.2
1.1
—
—
—
0
0
5
33
1.52
0.41
1.4
1.7
—
—
—
0
0
0
16
0.00
0.41
0.0
1.0
—
—
—
0
0
10
71
1.42
0.39
1.6
1.6
—
—
—
0
0
5
37
1.36
0.37
1.2
1.3
—
—
—
0
0
365
3573
1.11
0.36
21.0
12.7
39.7
40.4
%
1.03
272
2766
51
455
1.14
0.33
2.7
2.7
0.8
0.7
ug/l
0.36
33
274
27
235
1.16
0.26
1.3
1.3
—
—
—
0
0
37
330
1.13
0.26
4.4
4.2
2.4
21.7
ug/l
0.85
27
267
38
423
0.89
0.25
1.6
1.6
—
—
—
0
0
18
212
0.84
0.24
1.2
1.0
—
—
—
0
0
11
88
1.26
0.22
1.1
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
48
520
0.91
0.20
1.3
1.8
1.3
1.4
%
0.51
42
466
0
14
0.00
0.20
0.0
2.3
—
—
—
0
0
8
68
1.18
0.16
1.4
1.9
208.4
242.3
pmol/l
—
8
62
8
72
1.11
0.16
1.4
1.5
—
—
—
0
0
24
219
1.10
0.13
1.7
2.3
15.4
13.6
nmol/l
0.33
18
200
12
136
0.88
0.11
1.5
1.4
—
—
—
0
0
13
146
0.89
0.10
1.2
1.3
199.2
251.9
miu/ml
—
7
73
23
249
0.92
0.10
1.5
2.8
30.6
46.8
u/ml
0.39
23
241
13
145
0.89
0.09
1.3
1.9
—
—
—
0
0
6
58
1.03
0.08
1.8
2.0
12.8
13.1
%
—
6
58
6
71
0.84
0.07
1.3
1.5
—
—
—
0
0
33
314
1.05
0.07
1.2
1.2
58.0
161.1
iu/ml
2.33
14
129
8
94
0.85
0.06
1.3
1.6
—
—
—
0
0
16
149
1.08
0.05
1.3
1.4
—
—
—
0
0
13
120
1.09
0.05
1.2
1.5
—
—
—
0
0
75
760
0.98
0.02
1.5
1.4
—
—
—
0
0
12
113
1.06
0.02
1.2
1.5
—
—
—
0
0
12
113
1.06
0.02
1.2
1.5
—
—
—
0
0
12
113
1.06
0.02
1.2
1.5
—
—
—
0
0
12
113
1.06
0.02
1.2
1.5
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
2.7
—
0.7
—
0
6
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
5
52
0.96
0.00
1.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
20
200
1.00
0.00
1.4
1.6
—
—
—
0
0
0
9
0.00
0.00
0.0
1.8
—
1.3
—
0
9
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
8
83
0.96
0.00
1.6
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
65.7
—
0
6
Mortality – FinRegistry
↥Association
Association between endpoint H7_SCLERITIS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_SCLERITIS | 1.084 [0.86, 1.37] | 0.504 |
| Birth year | 1.001 [0.99, 1.01] | 0.834 |
During the follow-up period (1.1.1998 — 31.12.2019), 104 out of 1178 females with H7_SCLERITIS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_SCLERITIS | 1.021 [0.79, 1.31] | 0.872 |
| Birth year | 0.987 [0.98, 1.0] | 0.007 |
During the follow-up period (1.1.1998 — 31.12.2019), 90 out of 823 males with H7_SCLERITIS died.
Mortality risk
Mortality risk for people of age
years, who have H7_SCLERITIS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.093% | 0.155% |
| 5 | 0.755% | 1.052% |
| 10 | 1.801% | 2.761% |
| 15 | 3.691% | 5.513% |
| 20 | 6.633% | 9.676% |
Relationships between endpoints
↥Index endpoint: H7_SCLERITIS – Scleritis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data